PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277785
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Establishment of a Patient-derived Xenograft for Development of Personalized
      HER2-targeting Therapy in Gastric Cancer.
PG  - 287-293
AB  - BACKGROUND/AIM: To maximize success rate for development of HER2-targeted
      therapeutics, patient-derived xenograft (PDX) models reflecting HER2-positive
      gastric cancer (HER2(+) GC) patients were established. MATERIALS AND METHODS: GC 
      tissues obtained from surgery of GC patients were implanted into immune-deficient
      mice, and tumor tissue of HER2(+) PDXs were verified of the patient-mimic HER2
      expression by immunohistochemistry and explored for the feasibility by testing
      with Herceptin, the approved therapeutics and novel HER2 antibody therapeutics
      being developed. RESULTS: We obtained 5 cases of HER2(+) GC PDX models reflecting
      patient's GC tumor, consisting of 2 cases of HER2 3+ and 2 cases of HER2 2+.
      Novel HER2 antibody displayed significantly improved anti-cancer efficacy in
      combination with Herceptin. CONCLUSION: The HER2(+) GC PDX models were
      successfully established to be utilized for preclinical evaluation of
      HER2-targeting drugs and combined therapies for GC treatment, as an ideal
      platform of personalized tools for precision therapy.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Shin, Seol Hwa
AU  - Shin SH
AD  - ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
FAU - Park, Seok Soon
AU  - Park SS
AD  - ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
FAU - Ju, Eun Jin
AU  - Ju EJ
AD  - ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
FAU - Park, Jin
AU  - Park J
AD  - ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
FAU - Ko, Eun Jeong
AU  - Ko EJ
AD  - ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
FAU - Hwang, Jung Jin
AU  - Hwang JJ
AD  - ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Department of Convergence Medicine, ASAN Medical Center, University of Ulsan
      College of Medicine, Seoul, Republic of Korea.
FAU - Suh, Young-Ah
AU  - Suh YA
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
FAU - Jang, Se Jin
AU  - Jang SJ
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Department of Pathology, ASAN Medical Center, University of Ulsan College of
      Medicine, Seoul, Republic of Korea.
FAU - Lee, Jung Shin
AU  - Lee JS
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Department of Internal Medicine, ASAN Medical Center, University of Ulsan College
      of Medicine, Seoul, Republic of Korea.
FAU - Ko, Bong-Kook
AU  - Ko BK
AD  - Therapeutic Antibody Research Center, AbClon Inc., Seoul, Republic of Korea.
FAU - Kim, Kyu-Tae
AU  - Kim KT
AD  - Therapeutic Antibody Research Center, AbClon Inc., Seoul, Republic of Korea.
FAU - Lee, Jong-Seo
AU  - Lee JS
AD  - Therapeutic Antibody Research Center, AbClon Inc., Seoul, Republic of Korea.
FAU - Song, Si Yeol
AU  - Song SY
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Department of Radiation Oncology, ASAN Medical Center, University of Ulsan
      College of Medicine, Seoul, Republic of Korea.
FAU - Jeong, Seong-Yun
AU  - Jeong SY
AD  - ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea
      [email protected] [email protected]
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Department of Convergence Medicine, ASAN Medical Center, University of Ulsan
      College of Medicine, Seoul, Republic of Korea.
FAU - Choi, Eun Kyung
AU  - Choi EK
AD  - Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of
      Korea [email protected] [email protected]
AD  - Center for Advancing Cancer Therapeutics, ASAN Medical Center, Seoul, Republic of
      Korea.
AD  - Department of Radiation Oncology, ASAN Medical Center, University of Ulsan
      College of Medicine, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/pathology
MH  - Aged
MH  - Animals
MH  - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Middle Aged
MH  - Precision Medicine
MH  - Receptor, ErbB-2/*antagonists & inhibitors/immunology/metabolism
MH  - Stomach Neoplasms/*drug therapy/pathology
MH  - Trastuzumab/pharmacology/*therapeutic use
MH  - Tumor Burden/drug effects
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - *Patient-derived xenograft
OT  - *gastric cancer
OT  - *human epidermal growth factor receptor 2
OT  - *personalized treatment
EDAT- 2017/12/27 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/08/31 00:00 [received]
PHST- 2017/10/24 00:00 [revised]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 38/1/287 [pii]
AID - 10.21873/anticanres.12220 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):287-293. doi: 10.21873/anticanres.12220.